Christopher Ames, MD, director of spinal tumor and spinal deformity surgery at UC San Francisco Medical Center, was assisted by Patrick Maloney, MD, in the procedure.
Aprevo is the only spine technology to receive the FDA’s breakthrough device designation, according to the company.
The aprevo portfolio is designed to “eliminate the tedious and costly process of stock device inventory control and reprocessing,” Carlsmed CEO Mike Cordonnier said in a Feb. 23 news release.
More articles on spine:
Will disc replacement supersede spinal fusion? 7 spine surgeons weigh in
FDA clears two surgical robots focused on imaging, spine
These CMS changes would significantly improve spine care: 6 surgeons weigh in
